Halyard Health Inc (NYSE:HYH) has received an average recommendation of “Buy” from the eight ratings firms that are covering the company, MarketBeat.com reports. Two analysts have rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $47.00.
Several equities research analysts recently weighed in on HYH shares. Zacks Investment Research raised Halyard Health from a “sell” rating to a “hold” rating in a report on Thursday, October 19th. ValuEngine raised Halyard Health from a “hold” rating to a “buy” rating in a report on Saturday, November 4th. TheStreet downgraded Halyard Health from a “b-” rating to a “c+” rating in a report on Monday, October 30th. KeyCorp reaffirmed a “hold” rating on shares of Halyard Health in a report on Tuesday, October 17th. Finally, Stifel Nicolaus reissued a “buy” rating and issued a $52.00 target price on shares of Halyard Health in a report on Friday, November 3rd.
Institutional investors have recently added to or reduced their stakes in the business. Wells Fargo & Company MN lifted its holdings in Halyard Health by 5.8% in the third quarter. Wells Fargo & Company MN now owns 514,776 shares of the medical instruments supplier’s stock valued at $23,180,000 after acquiring an additional 28,265 shares during the period. Koch Industries Inc. acquired a new stake in Halyard Health in the second quarter valued at $297,000. Confluence Investment Management LLC lifted its holdings in Halyard Health by 2.5% in the fourth quarter. Confluence Investment Management LLC now owns 104,033 shares of the medical instruments supplier’s stock valued at $4,804,000 after acquiring an additional 2,579 shares during the period. TIAA CREF Investment Management LLC lifted its holdings in Halyard Health by 35.2% in the second quarter. TIAA CREF Investment Management LLC now owns 202,901 shares of the medical instruments supplier’s stock valued at $7,970,000 after acquiring an additional 52,881 shares during the period. Finally, Prudential Financial Inc. lifted its holdings in Halyard Health by 3.9% in the third quarter. Prudential Financial Inc. now owns 686,309 shares of the medical instruments supplier’s stock valued at $30,904,000 after acquiring an additional 25,680 shares during the period. 89.32% of the stock is owned by institutional investors.
Halyard Health (NYSE:HYH) last issued its quarterly earnings results on Wednesday, November 1st. The medical instruments supplier reported $0.60 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.47 by $0.13. Halyard Health had a return on equity of 8.65% and a net margin of 3.52%. The firm had revenue of $401.40 million during the quarter, compared to the consensus estimate of $394.54 million. During the same period last year, the company earned $0.48 earnings per share. The company’s revenue for the quarter was up 1.0% on a year-over-year basis. research analysts expect that Halyard Health will post 2.08 EPS for the current year.
WARNING: This piece was reported by Community Financial News and is the sole property of of Community Financial News. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of US & international copyright legislation. The original version of this piece can be read at https://www.com-unik.info/2018/02/03/halyard-health-inc-hyh-receives-consensus-recommendation-of-buy-from-analysts.html.
About Halyard Health
Halyard Health, Inc is a medical technology company. The Company operates through two segments: Medical Devices and Surgical and Infection Prevention (S&IP). The Medical Devices segment provides a portfolio of product offerings focused on pain management, respiratory and digestive health. The S&IP segment provides healthcare supplies and solutions that target the prevention of healthcare-associated infections.
Receive News & Ratings for Halyard Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halyard Health and related companies with MarketBeat.com's FREE daily email newsletter.